Study: Tharakan 2021, Journal of Clinical Medicine

Immunomodulatory Effect of Withania somnifera (Ashwagandha) Extract-A Randomized, Double-Blind, Placebo Controlled Trial with an Open Label Extension on Healthy Participants

Citation

Tharakan A, Shukla H, Benny IR, Tharakan M et al (2021). Journal of Clinical Medicine. PubMed id 34441940.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • Ashwagandha: cortisol, mood, skin, hair, heart, kidneys and liver Tier B thin

    B Healthy adults (number not stated in the abstract), 30-day blinded period then 30-day open-label extension (n=not stated in the abstract)

    Randomised, double-blind, placebo-controlled, 60 mg Withania somnifera extract.

    Blood levels of several immunoglobulins, cytokines and immune cell counts (including NK cells) rose in the ashwagandha group. No adverse events reported. The abstract reports lab markers, not fewer infections.

    As recorded in this card: Tharakan A, Shukla H, Benny IR, Tharakan M et al (2021), Journal of Clinical Medicine, [primary]

    Note: Lab markers only, no infection outcome, sample size not in the abstract. A rise in a marker is not shown to mean better protection.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.